Evaluation of long-term outcome following therapeutic mammaplasty: the effect of wound complication on initiation of adjuvant therapy and subsequent oncological outcome.

IF 1.1 4区 医学 Q3 SURGERY
R Rampal, S Jones, W Hogg, B Rengabashyam, B Hogan, R Achuthan, B Kim
{"title":"Evaluation of long-term outcome following therapeutic mammaplasty: the effect of wound complication on initiation of adjuvant therapy and subsequent oncological outcome.","authors":"R Rampal, S Jones, W Hogg, B Rengabashyam, B Hogan, R Achuthan, B Kim","doi":"10.1308/rcsann.2023.0095","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic mammaplasty (TM) facilitates large tumour resection while maintaining optimal aesthetic outcome. It carries higher wound complication risks, which may delay adjuvant therapy initiation. Whether this delay affects oncological outcome requires evaluation.</p><p><strong>Methods: </strong>Data were collected for consecutive patients receiving TM at the Leeds breast unit (2009-2017). A prospectively maintained database was used to determine tumour characteristics, wound complication rates, receipt of adjuvant therapy and breast cancer recurrence or death.</p><p><strong>Results: </strong>In total 112 patients (median age of 54 years) underwent 114 TM procedures. The most common histological subtypes were invasive ductal carcinoma (61.4%), invasive lobular carcinoma (13.2%) and ductal carcinoma in situ (13.2%). Of the patients, 88.2% had oestrogen receptor-positive cancer and 14% had human epidermal growth factor receptor-positive cancer; 26.3% had multifocal cancer. The median tumour size was 30mm. The median Nottingham Prognostic Index was 4.2. The local recurrence rate was 3.5% (median follow-up of 8.6 years). The 5- and 10-year disease-free survival (DFS) was 88.5% and 83.5%, and the equivalent overall survival (OS) rates were 94% and 83.5%. Wound complication rate was 23.6% (<i>n</i>=27), the commonest being wound infection (11.4%; <i>n</i>=13) and T-junction wound breakdown (10.5%; <i>n</i>=12). The median time to adjuvant therapy was 72 days (interquartile range [IQR] 56-90) for patients with wound complications, and 51 days (IQR 42-58) for those without. However, this delay did not affect DFS or OS (log-rank test; <i>p</i>=0.58 and <i>p</i>=0.94, respectively). This was confirmed on Cox regression analysis.</p><p><strong>Conclusion: </strong>Our study finding demonstrates that although wound complications after TM leads to a modest delay to adjuvant therapy, the long-term oncological outcomes were comparable with those in patients without wound complications.</p>","PeriodicalId":8088,"journal":{"name":"Annals of the Royal College of Surgeons of England","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the Royal College of Surgeons of England","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1308/rcsann.2023.0095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Therapeutic mammaplasty (TM) facilitates large tumour resection while maintaining optimal aesthetic outcome. It carries higher wound complication risks, which may delay adjuvant therapy initiation. Whether this delay affects oncological outcome requires evaluation.

Methods: Data were collected for consecutive patients receiving TM at the Leeds breast unit (2009-2017). A prospectively maintained database was used to determine tumour characteristics, wound complication rates, receipt of adjuvant therapy and breast cancer recurrence or death.

Results: In total 112 patients (median age of 54 years) underwent 114 TM procedures. The most common histological subtypes were invasive ductal carcinoma (61.4%), invasive lobular carcinoma (13.2%) and ductal carcinoma in situ (13.2%). Of the patients, 88.2% had oestrogen receptor-positive cancer and 14% had human epidermal growth factor receptor-positive cancer; 26.3% had multifocal cancer. The median tumour size was 30mm. The median Nottingham Prognostic Index was 4.2. The local recurrence rate was 3.5% (median follow-up of 8.6 years). The 5- and 10-year disease-free survival (DFS) was 88.5% and 83.5%, and the equivalent overall survival (OS) rates were 94% and 83.5%. Wound complication rate was 23.6% (n=27), the commonest being wound infection (11.4%; n=13) and T-junction wound breakdown (10.5%; n=12). The median time to adjuvant therapy was 72 days (interquartile range [IQR] 56-90) for patients with wound complications, and 51 days (IQR 42-58) for those without. However, this delay did not affect DFS or OS (log-rank test; p=0.58 and p=0.94, respectively). This was confirmed on Cox regression analysis.

Conclusion: Our study finding demonstrates that although wound complications after TM leads to a modest delay to adjuvant therapy, the long-term oncological outcomes were comparable with those in patients without wound complications.

治疗性乳房整形术后长期疗效评估:伤口并发症对开始辅助治疗和后续肿瘤疗效的影响。
简介治疗性乳房整形术(TM)有助于切除大块肿瘤,同时保持最佳的美观效果。它的伤口并发症风险较高,可能会延迟辅助治疗的开始。这种延迟是否会影响肿瘤结果需要评估:方法:收集利兹乳腺科接受TM治疗的连续患者的数据(2009-2017年)。结果:共有112名患者(中位年龄)接受了TM治疗:共有112名患者(中位年龄为54岁)接受了114例TM手术。最常见的组织学亚型为浸润性导管癌(61.4%)、浸润性小叶癌(13.2%)和导管原位癌(13.2%)。88.2%的患者雌激素受体阳性,14%的患者人表皮生长因子受体阳性,26.3%的患者为多灶性癌症。肿瘤大小中位数为 30 毫米。诺丁汉预后指数中位数为4.2。局部复发率为3.5%(中位随访8.6年)。5年和10年无病生存率(DFS)分别为88.5%和83.5%,总生存率(OS)分别为94%和83.5%。伤口并发症发生率为23.6%(27人),最常见的是伤口感染(11.4%;13人)和T型连接伤口破裂(10.5%;12人)。有伤口并发症的患者接受辅助治疗的中位时间为 72 天(四分位间距 [IQR] 56-90),无并发症的患者为 51 天(四分位间距 [IQR] 42-58)。然而,这种延迟并不影响 DFS 或 OS(对数秩检验;P=0.58 和 P=0.94)。Cox回归分析证实了这一点:我们的研究结果表明,虽然 TM 后的伤口并发症会导致辅助治疗的适度延迟,但长期肿瘤学结果与无伤口并发症的患者相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
316
期刊介绍: The Annals of The Royal College of Surgeons of England is the official scholarly research journal of the Royal College of Surgeons and is published eight times a year in January, February, March, April, May, July, September and November. The main aim of the journal is to publish high-quality, peer-reviewed papers that relate to all branches of surgery. The Annals also includes letters and comments, a regular technical section, controversial topics, CORESS feedback and book reviews. The editorial board is composed of experts from all the surgical specialties.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信